Fulgent Genetics (FLGT) Expected to Post Quarterly Earnings on Thursday

Fulgent Genetics (NASDAQ:FLGT) will likely be issuing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.65) per share and revenue of $86.30 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Fulgent Genetics (NASDAQ:FLGT) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.12). Fulgent Genetics had a negative return on equity of 4.93% and a negative net margin of 26.05%. The company had revenue of $85.39 million for the quarter, compared to analyst estimates of $94.00 million. On average, analysts expect Fulgent Genetics to post ($3.48) EPS for the current fiscal year and ($2.76) EPS for the next fiscal year.

Fulgent Genetics Stock Up 4.0%

Shares of NASDAQ:FLGT opened at $21.52 on Thursday. Fulgent Genetics has a 12 month low of $13.46 and a 12 month high of $31.04. The company’s 50-day moving average price is $20.72 and its two-hundred day moving average price is $19.58. The firm has a market cap of $592.12 million, a P/E ratio of -7.63 and a beta of 0.93.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on FLGT shares. Weiss Ratings raised shares of Fulgent Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. Piper Sandler increased their price target on shares of Fulgent Genetics from $15.00 to $19.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. Finally, Wall Street Zen raised shares of Fulgent Genetics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 29th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Fulgent Genetics has a consensus rating of “Hold” and a consensus price target of $27.50.

Insiders Place Their Bets

In related news, COO Jian Xie sold 2,127 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $19.66, for a total value of $41,816.82. Following the sale, the chief operating officer directly owned 359,924 shares of the company’s stock, valued at approximately $7,076,105.84. The trade was a 0.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Hanlin Gao sold 1,673 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $19.66, for a total value of $32,891.18. Following the completion of the sale, the insider owned 986,117 shares in the company, valued at approximately $19,387,060.22. This trade represents a 0.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 5,932 shares of company stock worth $117,156. 36.18% of the stock is currently owned by company insiders.

About Fulgent Genetics

Fulgent Genetics, Inc is a technology-driven clinical diagnostics company that develops and performs genetic testing. Its testing platform uses next-generation sequencing and other molecular technologies to analyze DNA and support the diagnosis, screening and management of inherited and acquired diseases.

The company offers a range of tests, including panels for hereditary cancer, reproductive health and inherited disorders, as well as tumor profiling and other specialized clinical testing services.